Investing.com - Monte Rosa Therapeutics (NASDAQ: GLUE) reported second quarter EPS of $-0.71, $0.01 worse than the analyst estimate of $-0.70. Revenue for the quarter came in at $0.00...
Monte Rosa Therapeutics, Inc. (GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M....
An analyst from JPMorgan maintained Monte Rosa Therapeutics (NASDAQ: GLUE) at 'overweight' and a price target of $31.00 from a prior price target of $36.00. Prior to this rating, Monte...
Investing.com - Monte Rosa Therapeutics (NASDAQ: GLUE) reported first quarter EPS of $-0.65, $0.04 better than the analyst estimate of $-0.69. Revenue for the quarter came in at $0.00 versus...
Monte Rosa Therapeutics, Inc. (GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka,...
Investing.com - Monte Rosa Therapeutics (NASDAQ: GLUE) reported first quarter EPS of $-0.63, worse than the analyst estimate of $-0.62. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Monte Rosa Therapeutics reported on Thursday third quarter {{erl-1174595||earnings that beat analysts' forecasts and revenue that was inline with expectations. Monte Rosa...
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Technology, Consumer Goods and Consumer Services sectors propelled shares lower. At the close in NYSE,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
